臨床婦人科産科74巻3号

2020年04月発行

今月の臨床 徹底解説！ 卵巣がんの最新治療―複雑化する治療を整理する

変貌する卵巣がん治療

著者： 佐藤豊実¹

所属機関： ¹筑波大学医学医療系産科婦人科学

ページ範囲：P.310 - P.315

文献概要

●LION試験の結果，一部の患者ではprimary debulking surgery時に後腹膜リンパ節郭清を行わないことが勧められるかもしれない．

●卵巣がんに使用できる分子標的薬が続々と登場し，シスプラチン，タキサン登場時のようなブレークスルーが起きている．

●新しい分子標的薬が登場し，その組み合わせは多彩であり，加えてパネル検査による個別化も進めば腫瘍内科医とのコラボレーションが必要となる可能性がある．

参考文献

1）Chang SJ, et al : Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer : a meta-analysis. Gynecol Oncol 130 : 493-498, 2013

2）Harter P, et al : A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms. N Engl J Med 380 : 822-832, 2019

3）Sugiyama T, et al : Clinical characteristics of clear cell carcinoma of the ovary : a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 88 : 2584-2589, 2000

4）Zang RY, et al : Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma : who benefits? Cancer 100 : 1152-1161, 2004

5）Onda T, et al : Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma : proposal for patients selection. Br J Cancer 92 : 1026-1032, 2005

6）Chi DS, et al : Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 106 : 1933-1939, 2006

7）Harter P, et al : Surgery in recurrent ovarian cancer : the Arbeitsgemeinschaft Gynaekologische Onkologie（AGO）DESKTOP OVAR trial. Ann Surg Oncol 10 : 1702-1710, 2006

8）Salani R, et al : Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer : analysis of prognostic factors and survival outcome. Cancer 109 : 685-691, 2007

9）Zang RY, et al : Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort. Br J Cancer 105 : 890-896, 2011

10）Tian WJ, et al : A risk model for secondary cytoreductive surgery in recurrent ovarian cancer : an evidence-based proposal for patient selection. Ann Surg Oncol 19 : 597-604, 2012

11）Minaguchi T, et al : Proposal for selection criteria of secondary cytoreductive surgery in recurrent epithelial ovarian, tubal, and peritoneal cancers. Int J Clin Oncol 21 : 573-579 2016

12）Omura G, et al : A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma : a Gynecologic Oncology Group study. Cancer 57 : 1725-1730, 1986

13）Omura GA, et al : Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma : a Gynecologic Oncology Group study. J Clin Oncol 7 : 457-465, 1989

14）McGuire III WP, et al : A phase III randomized study of cyclophosphamide and cisplatin versus paclitaxel and cisplatin in patients with suboptimal stage III and IV epithelial ovarian cancer. N Engl J Med 334 : 1-6, 1996

15）Ozols R, et al : Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resectedstage III ovarian cancer : a Gynecologic Oncology Groupstudy. J Clin Oncol 21 : 3194-3200, 2003

16）Copeland LJ, et al : Clinical trials of newer regimens for treating ovarian cancer : the rationale for Gynecologic Oncology Group Protocol GOG 182-ICON5. Gynecol Oncol 90 : S1-S7, 2003

17）Bookman M, et al : Evaluation of new platinum based treatment regimens in advancedstage ovarian cancer : a phase III trial of the Gynecologic Cancer Intergroup. J Clin Oncol 27 : 1419-1425, 2009

18）Burger RA, et al : Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365 : 2473-2483, 2011

19）Moore K, et al : Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 379 : 2495-2505, 2018

20）Pujade-Lauraine E, et al : Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer : The AURELIA open-label randomized phase III trial. J Clin Oncol 32 : 1302-1308, 2014

21）Aghajanian C, et al : OCEANS : a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer J Clin Oncol 30 : 2039-2045, 2012

22）Ledermann J, et al : Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 366 : 1382-1392, 2012

23）Pujade-Lauraine E, et al : Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation（SOLO2/ENGOT-Ov21）: a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 18 : 1274-1284, 2017

24）Le DT, et al : Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357 : 409-413, 2017